Clinical implications of basic science discoveries: Janus resurrected - Two faces of B cell and plasma cell biology

American Journal of Transplantation

Volumn 15, Issue 1, 2015, Pages 39-43

  Woodle, E S ^a   Rothstein, D M ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 27; INTERLEUKIN 35; TOLL LIKE RECEPTOR; MONOCLONAL ANTIBODY;

B LYMPHOCYTE; CELL POPULATION; CYTOKINE PRODUCTION; CYTOLOGY; EFFECTOR CELL; GRAFT SURVIVAL; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; IMMUNOSUPPRESSIVE TREATMENT; ORGAN TRANSPLANTATION; PLASMA CELL; REGULATORY T LYMPHOCYTE; REVIEW; ANTIGEN PRESENTATION; AUTOIMMUNE DISEASES; COMMUNICABLE DISEASES; IMMUNOLOGY; PROGNOSIS;

ANTIBODIES, MONOCLONAL; ANTIGEN PRESENTATION; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; COMMUNICABLE DISEASES; HUMANS; PLASMA CELLS; PROGNOSIS;

EID: 84919664607     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13028     Document Type: Review

References (32)

1. Mao Q, Terasaki PI, Cai J, et al. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant 2007; 7: 864-871.
2. Everly MJ, Everly JJ, Arend LJ, et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009; 9: 1063-1071.
3. Wojciechowski W, Harris DP, Sprague F, et al. Cytokine-producing effector B cells regulate type 2 immunity to H. polygyrus. Immunity 2009; 30: 421-433.
4. Barr TA, Shen P, Brown S, et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med 2012; 209: 1001-1010.
5. Bermejo DA, Jackson SW, Gorosito-Serran M, et al. Trypanosoma cruzi trans-sialidase initiates a program independent of the transcription factors RORgammat and Ahr that leads to IL-17 production by activated B cells. Nat Immunol 2013; 14: 514-522.
6. Lund FE, Randall TD., Effector and regulatory B cells: Modulators of CD4+ T cell immunity. Nat Rev Immunol 2010; 10: 236-247.
7. Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons JA., Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 2006; 180: 63-70.
8. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-2581.
9. Vo AA, Peng A, Toyoda M, et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010; 89: 1095-1102.
10. Fehr T, Rusi B, Fischer A, Hopfer H, Wuthrich RP, Gaspert A., Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. Transplantation 2009; 87: 1837-1841.
11. Sautenet B, Blancho G, Buchler M, et al. One year results of the effects of Rituximab on acute humoral rejection in renal transplantation: RITUX ERAH, a multicentre randomized placebo controlled trial [abstract]. Am J Transplant 2013; 13: 112.
12. Clatworthy MR., B-cell regulation and its application to transplantation. Transpl Int 2014; 27: 117-128.
13. Dilillo DJ, Matsushita T, Tedder TF., B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann N Y Acad Sci 2010; 1183: 38-57.
14. Mauri C, Ehrenstein MR., The 'short' history of regulatory B cells. Trends Immunol 2008; 29: 34-40.
15. Mauri C, Blair PA., Regulatory B cells in autoimmunity: Developments and controversies. Nat Rev Rheumatol 2010; 6: 636-643.
16. Ding Q, Yeung M, Camirand G, et al. Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice. J Clin Invest 2011; 121: 3645-3656.
17. Lee KM, Kim JI, Stott R, et al. Anti-CD45RB/anti-TIM-1-induced tolerance requires regulatory B cells. Am J Transplant 2012; 12: 2072-2078.
18. Cherukuri A, Rothstein DM, Clark B, et al. Immunologic human renal allograft injury associates with an altered IL-10/TNF-alpha expression ratio in regulatory B cells. J Am Soc Nephrol 2014; 25: 1575-1585.
19. Thaunat O, Morelon E, Defrance T., Am"B"valent: Anti-CD20 antibodies unravel the dual role of B cells in immunopathogenesis. Blood 2010; 116: 515-521.
20. Clatworthy MR, Watson CJ, Plotnek G, et al. B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med 2009; 360: 2683-2685.
21. Walsh RC, Alloway RR, Girnita AL, Woodle ES., Proteasome inhibitor-based therapy for antibody-mediated rejection. Kidney Int 2012; 81: 1067-1074.
22. Shen P, Roch T, Lampropoulou V, et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature 2014; 507: 366-370.
23. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM., B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002; 3: 944-950.
24. Yanaba K, Bouaziz JD, Matsushita T, Tsubata T, Tedder TF., The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J Immunol 2009; 182: 7459-7472.
25. Miles K, Heaney J, Sibinska Z, et al. A tolerogenic role for Toll-like receptor 9 is revealed by B-cell interaction with DNA complexes expressed on apoptotic cells. Proc Natl Acad Sci U S A 2012; 109: 887-892.
26. Olson BM, Sullivan JA, Burlingham WJ., Interleukin 35: A key mediator of suppression and the propagation of infectious tolerance. Front Immunol 2013; 4: 315.
27. Dang VD, Hilgenberg E, Ries S, Shen P, Fillatreau S., From the regulatory functions of B cells to the identification of cytokine-producing plasma cell subsets. Curr Opin Immunol 2014; 28C: 77-83.
28. Rauch PJ, Chudnovskiy A, Robbins CS, et al. Innate response activator B cells protect against microbial sepsis. Science 2012; 335: 597-601.
29. Gray D, Gray M, Barr T., Innate responses of B cells. Eur J Immunol 2007; 37: 3304-3310.
30. Minoprio P, Burlen O, Pereira P, et al. Most B cells in acute Trypanosoma cruzi infection lack parasite specificity. Scand J Immunol 1988; 28: 553-561.
31. Matsushita T, Horikawa M, Iwata Y, Tedder TF., Regulatory B cells (B10 cells) and regulatory T cells have independent roles in controlling experimental autoimmune encephalomyelitis initiation and late-phase immunopathogenesis. J Immunol 2010; 185: 2240-2252.
32. Hartung HP, Kieseier BC., Atacicept: Targeting B cells in multiple sclerosis. Ther Adv Neurol Disord 2010; 3: 205-216.